NCT07020221 2026-03-09A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid TumorsVerastem, Inc.Phase 1/2 Recruiting295 enrolled
NCT05180799 2025-06-15A Phase 1/2 Study of BA3071 in Patients With Solid TumorsBioAtla, Inc.Phase 1/2 Active not recruiting320 enrolled
NCT05431270 2025-01-31Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)Phanes TherapeuticsPhase 1/2 Recruiting40 enrolled
NCT04430933 2021-08-18A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLCNextCure, Inc.Phase 1/2 Withdrawn